BR112019025583A2 - Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3 - Google Patents

Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3

Info

Publication number
BR112019025583A2
BR112019025583A2 BR112019025583-4A BR112019025583A BR112019025583A2 BR 112019025583 A2 BR112019025583 A2 BR 112019025583A2 BR 112019025583 A BR112019025583 A BR 112019025583A BR 112019025583 A2 BR112019025583 A2 BR 112019025583A2
Authority
BR
Brazil
Prior art keywords
region
genetically modified
specific antibodies
multimeric proteins
modified multi
Prior art date
Application number
BR112019025583-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Chiu Mark
Zwolak Adam
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of BR112019025583A2 publication Critical patent/BR112019025583A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
BR112019025583-4A 2017-06-05 2018-06-04 Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3 BR112019025583A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515316P 2017-06-05 2017-06-05
US62/515,316 2017-06-05
PCT/IB2018/053997 WO2018224951A2 (en) 2017-06-05 2018-06-04 Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations

Publications (1)

Publication Number Publication Date
BR112019025583A2 true BR112019025583A2 (pt) 2020-06-16

Family

ID=64458754

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025583-4A BR112019025583A2 (pt) 2017-06-05 2018-06-04 Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3

Country Status (10)

Country Link
US (1) US11149094B2 (https=)
EP (1) EP3634486A4 (https=)
JP (1) JP7710827B2 (https=)
KR (1) KR20200014379A (https=)
CN (1) CN110785185B (https=)
AU (1) AU2018281045A1 (https=)
BR (1) BR112019025583A2 (https=)
CA (1) CA3065171A1 (https=)
MX (1) MX2019014576A (https=)
WO (1) WO2018224951A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
KR102014554B1 (ko) 2011-06-02 2019-08-26 다이액스 코포레이션 Fc 수용체 결합 단백질
CN104011207B (zh) 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
WO2017027325A1 (en) * 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
US11459405B2 (en) * 2015-12-28 2022-10-04 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2019000105A1 (en) * 2017-06-30 2019-01-03 Zymeworks Inc. STABILIZED CHIMERIC FABES
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
US20220267475A1 (en) * 2019-06-25 2022-08-25 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-tigit bispecific antibody, preparation method therefor and application thereof
KR20220032076A (ko) * 2019-07-09 2022-03-15 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 Tnf-알파 및 il-1베타에 대한 이중특이적 항체 및 이의 용도
EP3999186A1 (en) * 2019-07-17 2022-05-25 BioInvent International AB Antibody combinations for treatment of cancer in specific patients
US20220306735A1 (en) * 2019-08-30 2022-09-29 University Of Kansas Compositions including igg fc mutations and uses thereof
WO2021051136A1 (en) * 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
EP4034570A4 (en) * 2019-09-27 2023-10-25 Agenus Inc. HETERODIMERIC PROTEINS
TW202128131A (zh) * 2020-01-17 2021-08-01 大陸商信達生物制藥(蘇州)有限公司 重組抗程式性細胞死亡受體1和抗分化抗原簇137雙特異性抗體製劑及其用途
US20230114372A1 (en) * 2020-02-07 2023-04-13 Avantor Performance Materials, Llc Polypeptide affinity ligands and methods of using
EP4126929A1 (en) * 2020-03-25 2023-02-08 Eli Lilly and Company Multispecific binding proteins and methods of developing the same
EP4132969A4 (en) * 2020-04-07 2024-05-01 Fred Hutchinson Cancer Center ANTI-MESOTHELIN ANTIGEN-BINDING MOLECULES AND USES THEREOF
US11739137B2 (en) * 2020-10-30 2023-08-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies to SARS-CoV-2 nucleocapsid protein
US20250026784A1 (en) * 2021-11-29 2025-01-23 Tosoh Corporation Separation method of antibody
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
WO2024213119A1 (en) * 2023-04-14 2024-10-17 Adaptocue, Llc Ph-sensitive cd47-binding domains and uses thereof
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) * 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
EP2087111A2 (en) * 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JP5816170B2 (ja) * 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
CA2766166A1 (en) 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
TWI812066B (zh) * 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CN112812184A (zh) * 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
RU2732151C2 (ru) * 2011-09-30 2020-09-11 Чугаи Сейяку Кабусики Кайся Библиотека зависимых от концентрации ионов связывающих молекул
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
JP6124800B2 (ja) * 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
PT2825559T (pt) * 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
EP2857419B1 (en) * 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
EP3795215A1 (en) * 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
KR102216003B1 (ko) 2013-03-15 2021-02-16 얀센 바이오테크 인코포레이티드 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
WO2015034000A1 (ja) * 2013-09-04 2015-03-12 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
CN110627907B (zh) * 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
TW201619188A (zh) * 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
LT3129406T (lt) * 2014-04-11 2019-04-10 Medimmune, Llc Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus
CN106255704A (zh) 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
KR101860280B1 (ko) * 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN114773470A (zh) * 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
KR102095096B1 (ko) 2015-08-26 2020-03-30 바이슨 테라퓨틱스 인크. 다중특이적 항체 플랫폼 및 관련 방법
GB201515745D0 (en) 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins

Also Published As

Publication number Publication date
JP7710827B2 (ja) 2025-07-22
AU2018281045A1 (en) 2019-12-12
CA3065171A1 (en) 2018-12-13
EP3634486A2 (en) 2020-04-15
WO2018224951A3 (en) 2019-02-14
US11149094B2 (en) 2021-10-19
JP2020522266A (ja) 2020-07-30
CN110785185B (zh) 2024-05-24
EP3634486A4 (en) 2021-03-31
KR20200014379A (ko) 2020-02-10
US20180346605A1 (en) 2018-12-06
CN110785185A (zh) 2020-02-11
MX2019014576A (es) 2020-07-29
RU2019144115A3 (https=) 2022-02-10
RU2019144115A (ru) 2021-07-09
WO2018224951A2 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
BR112019025583A2 (pt) Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CO2019009365A2 (es) Anticuerpos anti-lag3
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
MX375524B (es) Anticuerpos anti-axl.
CU20170074A7 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CR20160450A (es) Anticuerpos multiespecificos
MX2021014956A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
CR20170511A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX2016005781A (es) Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t.
EP3003062C0 (en) PRODUCTION OF DRIED VEGETABLE PROTEIN PRODUCTS WITH REDUCED ASTRINGENCY
CR20170086A (es) Terapias de combinación con anticuerpos anti-cd38
EP3221446C0 (en) IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLS
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
CR20150284A (es) Terapia de combinación de anticuerpos anti-her3 y anti-her2
MX2016016883A (es) Anticuerpo anti-axl.
MX384491B (es) Cambio de temperatura para una expresion con mayor rendimiento de polipeptidos en levaduras y otras celulas transformadas.
UY37035A (es) MOLÉCULAS DE ANTICUERPO MULTIESPECÍFICO CON ESPECIFICIDAD POR TNF-ALFA, IL-17A e IL-17F
HUE063273T2 (hu) Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
EA201690793A1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c
UY35392A (es) Anticuerpos humanos que se unen al tnf-alfa humano y métodos para prepararlos
EP3448884C0 (en) Engineered mammalian cells for production of recombinant proteins
DK3127917T3 (da) Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof
BR112016019389A8 (pt) Vacina, e, peptídeo

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.